MedTrace Logo

NFAT-regulated Gene Expression After Tacrolimus

NCT03315858 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-02-03

No results posted yet for this study

Summary

Aim of the study is measurement of NFAT-RGE (IL-2 (interleukin-2), IFN-γ (interferon-gamma), GM-CSF (granulocyte monocyte colony stimulating factor)) after tacrolimus (TAC) in de-novo immunosuppressed patients after liver transplantation (LT), to test the hypothesis that in de-novo TAC patients receiving mycophenolate mofetil (MMF) and steroids after LT there is an inverse correlation of NFAT-RGE and TAC peak levels at 1.5 hours after TAC intake.

Conditions

  • NFAT Regulated Gene Expression in Tacrolimus Treated Patients

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-18
Primary Completion
2021-11-29
Completion
2021-11-29

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03315858 on ClinicalTrials.gov